October 2-5, 2020
Westin Copley Place
Boston, Massachusetts

Notice of Termination

The American Association for Cancer Research (AACR) has made the difficult decision, after careful consideration and a comprehensive evaluation of currently available information related to the novel coronavirus (COVID-19) outbreak, to terminate the AACR Conference on Myeloma and Plasma Cell Dyscrasias originally scheduled for October 2-5, 2020, in Boston, Massachusetts.

We recognize that the new data, exchange of information, and opportunities for collaboration offered by this meeting are highly valued by the myeloma research community; therefore, we are working to reschedule the conference as soon as possible. Information on the rescheduled meeting will posted to our website once it becomes available.

If you have a room reservation at the Westin Copley Place, your cancellation will be accepted at no charge up to 72 hours in advance of your scheduled check-in date; please contact the hotel at (617) 262-9600  to cancel your reservation as soon as possible. Many airlines have adjusted their rebooking and cancellation policies in response to the COVID-19 crisis.  Please contact your airline or booking agent directly to cancel your travel arrangements to Boston. 

The AACR deeply appreciates your patience and understanding during this unfortunate situation.  Please look for emails in the coming months as we work to reschedule this program as soon as possible. If you have any questions, please email [email protected].

Our heartfelt sympathies go out to everyone who has been impacted by this global health crisis.  Thank you for your dedication to the AACR and to its mission.

Conference Cochairs

Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, Massachusetts
Irene Ghobrial, Dana-Farber Cancer Institute, Boston, Massachusetts

Myeloma is one of the most commonly diagnosed blood cancers in the United States, with an estimated 32,270 new cases in 2020. Patient outcomes have improved over the last few years due to the development and FDA approval of novel therapeutics such as immunomodulatory agents (lenalidomide), immunotherapeutics (daratumumab), and proteasome inhibitors (bortezomib). New therapeutic options remain a priority to counter a lack of response to treatment and treatment resistance or relapse. This first AACR conference on myeloma and plasma cell dyscrasias will explore new advances in basic and translational cancer science in hopes of improving clinical outcomes.

Continuing Medical Education Activity AMA PRA Category 1 Credits^TM available